Spotlight on Mobocertinib (TAK-788) in NSCLC with EGFR Exon 20 Insertion Mutations
Shannon S Zhang,1 Viola W Zhu1,2 1University of California, Irvine School of Medicine, Department of Medicine, Orange, CA, USA; 2Chao Family Comprehensive Cancer Center, Orange, CA, USACorrespondence: Viola W ZhuUniversity of California, Irvine School of Medicine, Department of Medicine, 200 S Manch...
Saved in:
Main Authors: | Zhang SS, Zhu VW |
---|---|
Format: | article |
Language: | EN |
Published: |
Dove Medical Press
2021
|
Subjects: | |
Online Access: | https://doaj.org/article/5baf978ecbe94f9e9c65f45036a12bcd |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Patients harboring uncommon EGFR exon 19 deletion-insertion mutations respond well to first-generation EGFR inhibitors and osimeritinib upon acquisition of T790M
by: Yurong Wang, et al.
Published: (2021) -
Severe Psychiatric Symptoms in a Patient With EGFR Exon-20 Insertion Mutation Receiving Mobocertinib: A Case Report
by: Josette Kamel, BA, et al.
Published: (2021) -
Identification of lncRNA–miRNA–mRNA Networks Linked to Non-small Lung Cancer Resistance to Inhibitors of Epidermal Growth Factor Receptor
by: Ting Wang, et al.
Published: (2021) -
Role of afatinib in the treatment of advanced lung squamous cell carcinoma
by: Vavalà T
Published: (2017) -
Afatinib for the treatment of advanced non-small-cell lung cancer harboring an epidermal growth factor receptor exon 18 E709_T710delinsD mutation: a case report
by: Lander Van Acker, et al.
Published: (2021)